173 related articles for article (PubMed ID: 37388747)
1. PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.
Li P; Wang W; Wang S; Cao G; Pan T; Huang Y; Wan H; Zhang W; Huang Y; Jin H; Wang Z
Front Immunol; 2023; 14():1145481. PubMed ID: 37388747
[TBL] [Abstract][Full Text] [Related]
2. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model.
Wan H; Yang X; Sang G; Ruan Z; Ling Z; Zhang M; Liu C; Hu X; Guo T; He J; Liu D; Pei J
Aging (Albany NY); 2023 Oct; 15(20):11244-11267. PubMed ID: 37857018
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
5. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract][Full Text] [Related]
6. TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.
Chaojun L; Pengping L; Yanjun L; Fangyuan Z; Yaning H; Yingbo S; Qi C; Hui L
Aging (Albany NY); 2023 Nov; 15(22):12890-12906. PubMed ID: 37950731
[TBL] [Abstract][Full Text] [Related]
7. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
8. A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.
Wen H; Zhong Y; Yin Y; Qin K; Yang L; Li D; Yu W; Yang C; Deng Z; Hong K
Int J Biol Sci; 2022; 18(7):2898-2913. PubMed ID: 35541893
[TBL] [Abstract][Full Text] [Related]
9. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
Zhou M; Luo C; Zhou Z; Li L; Huang Y
J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
[TBL] [Abstract][Full Text] [Related]
10. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
11. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
[TBL] [Abstract][Full Text] [Related]
12. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
14. Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.
Si Y; Yue J; Liu Z; Li M; Du F; Wang X; Dai Z; Hu N; Ju J; Gao S; Wang X; Yuan P
Int J Nanomedicine; 2021; 16():1913-1926. PubMed ID: 33707946
[TBL] [Abstract][Full Text] [Related]
15. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
[TBL] [Abstract][Full Text] [Related]
16. Histological spatial analysis on the induction of PD-L1
Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
18. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
19. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis.
Zhu H; Yang K; Yao H; Chen X; Yan S; He Y; Cao Y; Luo J; Wang D
Int J Nanomedicine; 2023; 18():3109-3124. PubMed ID: 37323948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
